Sferrazza Papa GF, Dellacà R, Brusasco V. Severity grading of chronic obstructive pulmonary disease: the confounding effect of phenotype and thoracic gas compression. J Appl Physiol 118: 796 -802, 2015. First published November 20, 2014 doi:10.1152/japplphysiol.00801.2014.-Current guidelines recommend severity of chronic obstructive pulmonary disease be graded by using forced expiratory volume in 1 s (FEV 1). But this measurement is biased by thoracic gas compression depending on lung volume and airflow resistance. The aim of this study was to test the hypothesis that the effect of thoracic gas compression on FEV1 is greater in emphysema than chronic bronchitis because of larger lung volumes, and this influences severity classification and prognosis. FEV 1 was simultaneously measured by spirometry and body plethysmography in 47 subjects with dominant emphysema and 51 with dominant chronic bronchitis. Subjects with dominant emphysema had larger lung volumes, lower diffusion capacity, and lower FEV 1 than those with dominant chronic bronchitis. However, FEV 1-pl, patient-centered variables (dyspnea, quality of life, exercise tolerance, exacerbation frequency), arterial blood gases, and respiratory impedance were not significantly different between groups. Using FEV 1-pl instead of FEV1 shifted severity distribution toward less severe classes in dominant emphysema more than chronic bronchitis. The body mass, obstruction, dyspnea, and exercise (BODE) index was significantly higher in dominant emphysema than chronic bronchitis, but this difference significantly decreased when FEV 1-pl was substituted for FEV1. In conclusion, the FEV 1 is biased by thoracic gas compression more in subjects with dominant emphysema than in those with chronic bronchitis. This variably and significantly affects the severity grading systems currently recommended.
EVER SINCE the pioneering work of Tiffeneau (34) , the forced expiratory volume in 1 s (FEV 1 ) has been used as the key measurement of lung function for both diagnosis and severity assessment of obstructive lung disorders. 1 The underlying rationale is grounded on the concept that maximal expiratory flow, and thus the FEV 1 , decreases in disease, and this is the result of variable combinations of decrease in lung elastic recoil, decrease in airway size at choke point, increase in resistance upstream from the flow limiting segment, and increased airway collapsibility downstream from this segment (17) . However, this analysis does not consider that during forced expiration thoracic gas is compressed, because the expiratory pressure is well in excess to that necessary to generate maximal flow (17) . As a result of the large effort, lung volume and thus recoil will decrease. This will cause a decrease of driving pressure and transmural pressure at choke point, which can explain why the FEV 1 is systematically less than that measured in body plethysmograph (FEV 1-pl ) by the amount of thoracic gas compression volume (TGCV) (21) . Confirmatory evidence for this has been brought by Krowka et al. (21) by showing that with decreasing expiratory effort TGCV to a minimal value the FEV 1 becomes similar to FEV 1-pl . In addition to the expiratory effort, airflow resistance and absolute lung volume crucially contribute to increase TGCV (17, 18) , and thus the difference between FEV 1-pl and FEV 1 (32, 33) .
Current international guidelines and strategy documents (9, 25a, 26, 29, 31, 35) recommend severity of chronic obstructive pulmonary disease (COPD) be graded by the FEV 1 reduction below predicted values, irrespective of the underlying mechanisms. This is justified by the fact that expiratory flow limitation in COPD may be equally due to intrinsic airway narrowing, the characteristic feature of chronic bronchitis, or reduced lung elastic recoil, the characteristic feature of emphysema (6) . However, emphysema is also characterized by an increase in absolute lung volume, thus exposing a larger amount of thoracic gas to compression during a forced expiratory maneuver. Therefore, it can be hypothesized that for a given airway resistance, the FEV 1 overestimates the magnitude of airflow limitation in subjects with dominant emphysema compared with those with dominant bronchitis, and this may confound severity classification and prognosis (9, 25a, 26, 29, 31, 35) .
This study was designed to test this hypothesis by comparing FEV 1 and compression-free FEV 1 measured in a body plethysmograph (FEV 1-pl ) with absolute lung volumes, respiratory impedance, diffusion capacity, arterial gas tensions, dyspnea, quality of life, exercise performance, and exacerbations rate in two groups of COPD subjects with either dominant emphysema or chronic bronchitis. The impact of thoracic gas compression on different severity classification systems was estimated by substituting FEV 1-pl for FEV 1 .
METHODS

Subjects.
The study included 98 subjects with a clinical diagnosis of COPD (31) and not completely reversible airflow obstruction documented by a post-bronchodilator FEV 1 to vital capacity (VC) ratio (FEV1/VC) below the lower limit of normality and total lung capacity within or above the limits of normality (27) . Severity of disease was graded using the criteria proposed by the Global Initiative for Obstructive Lung Disease (GOLD) in 2007 (31) and 2013 (35) , and the body mass index, obstruction, dyspnea, and exercise capacity (BODE) index (8) .
All subjects were required to be in stable, clinical conditions and not to have suffered from respiratory exacerbations in the previous 4 wk. Subjects with a history suggestive of bronchial asthma were excluded. Prior to each study session, long-acting ␤ 2-agonists (salmeterol or formoterol) were suspended for at least 12 h, and tiotropium for 24 h. No subject was taking indacaterol or muscarinic antagonists other than tiotropium. The study protocol was approved by the S. Luigi Hospital Ethics Committee (Orbassano, Torino) (No. 103, 23-06-2006) , and written informed consent was obtained from each subject prior to the study.
Study design. On a prestudy day, subjects underwent clinical examination, evaluation for inclusion and exclusion criteria, and assessment of clinical stability.
On a first study day, a 3-ml arterial blood sample was drawn for PaO 2 and PaCO2 measurements (ABL 520, Radiometer, Copenhagen, Denmark). Then the Medical Research Council (MRC) questionnaire for dyspnea and the Saint George's Respiratory Questionnaire (SGRQ) were administered. A chest X-ray with posterior-anterior and right-left projections was taken, if not available over the previous 6 mo. Exacerbations were defined according to Vestbo et al. (35) , and their number recorded over the last two years.
On a second study day, the patients underwent full lung function examination. Spirometry and absolute lung volumes were obtained with the subjects sitting in a body plethysmograph (Autobox, SensorMedics, CA). After at least four regular breaths, thoracic gas volume was measured with the subject panting against a closed shutter at a frequency slightly Ͻ1 Hz with his and/or her cheeks supported by hands. Then the shutter was opened and the subject took a full deep breath to total lung capacity (TLC) before forcefully expiring to residual volume (RV) for at least 6 s. This maneuver allowed calculating functional residual capacity (FRC) from thoracic gas volume corrected for any difference between the volume at which the shutter was closed and the average end-expiratory tidal volume of the four preceding regular breaths, TLC, RV, VC, and FEV 1. Compressionfree FEV1 was simultaneously obtained by plotting mouth flow against change in plethysmographic volume to measure FEV1-pl (Fig. 1) . Three sets of technically acceptable maneuvers were obtained, and appropriately selected values (24, 36) were retained for analysis. Respiratory impedance was measured by a forced oscillation technique (FOT) previously described (12, 15) . Sinusoidal pressure oscillations (5 Hz, ϳ2 cmH 2O peak-to-peak) were generated by a loudspeaker with a diameter of 16 cm (model CW161N, Ciare, Italy) and applied at the mouth. The loudspeaker was mounted in a rigid plastic box and connected in parallel to a mesh pneumotachograph and mouthpiece on one side and to a low-resistance high-inertance tube (overall load at tidal breathing frequency, 0.98 cmH 2O·l Ϫ1 ·s) on the other side. Airway opening pressure and flow were measured by piezoresistive transducers (DCXL10DS and DCXL01DS Sensortechnics, Germany, respectively) and sampled at 200 Hz. A 15-l·min Ϫ1 bias flow of air generated by an air pump (CMP08, 3A Health Care, Italy) was used to reduce dead space to about 35 ml. Respiratory resistance and reactance were computed by a least squares algorithm (19, 20) at 5 Hz (R 5 and X5, respectively) and 19 Hz (R19 and X19, respectively). Artifacts due to glottis closure or expiratory airflow limitation were avoided by discarding breaths showing any of the following: 1) tidal volume Ͻ0.1 liters or Ͼ2.0 liters, 2) difference between measured flow oscillation and ideal sine wave with the same Fourier coefficients Ͼ0.2 (23), and 3) ratio of minimum to average X Ͼ 3.5 (14) . Measurements were taken during two sets of maneuvers, each consisting of 2-min tidal breathing on which mean R 5, R19, R5-19, and X5 were retained for analysis. Of the main function parameters of the FOT, R5 was taken as an index of overall airflow resistance of the respiratory system, R19 as an index of central airways resistance, R5-19 as an index of serial or peripheral heterogeneous ventilation, and X5 as an index of capacitative component of the respiratory system. Tidal volume (VT), breathing frequency (BF), and minute ventilation (V E) were averaged over the same tidal breaths used for FOT data collection. Single-breath DLCO was measured following the recommendation of the American Thoracic Society and European Respiratory Society (22) and 6-min walking distance (6MWD) according to ATS guidelines (3) .
Predicted values for the spirometry and lung volumes were from Quanjer et al. (30) . To estimate predicted FEV 1-pl, the predicted FEV1 was increased by 4.5%. This was the difference between FEV1-pl and FEV1 observed in a group of 81 healthy subjects [31 women and 50 men, aged 46 Ϯ 12 yr, with a body mass index (BMI) of 24 Ϯ 3 Data analysis. At the end of studies, subjects were grouped depending on dominant phenotype, i.e., chronic bronchitis or emphysema (Table 1) , based on the clinical and radiological score (CRS) proposed by Pistolesi et al. (28) . This score was obtained by a multivariate model with the following independent variables: sputum purulence, adventitious chest sounds, chest hyperresonance, FEV 1/ VC, radiographic signs of increased vascular markings, bronchial wall thickening, reduced lung density, and increased lung volume. A score Ͼ0.56 was taken as suggestive of dominant emphysema and Յ0.56 of dominant chronic bronchitis (28) .
Differences in baseline characteristics between groups were assessed for statistical significance by unpaired t-test. Betweenwithin group data were tested by a mixed repeated measure ANOVA. Categorical data were compared by Fischer's exact test with Freeman-Halton's extension for 2 ϫ 4 contingency tables when appropriate. Values of P Ͻ 0.05 were considered statistically significant. Data are presented as means Ϯ standard deviation. Statistical analyses were done by StatSoft Statistica and VassarStats website packages.
RESULTS
The two groups were well matched for anthropometric characteristics except for BMI, which was slightly lower in the dominant emphysema group (Table 1) . Subjects with dominant emphysema had significantly lower D L CO, D L CO/V A , and FEV 1 and significantly larger TLC, FRC, and RV than subjects with dominant chronic bronchitis (Table 1) . However, neither FEV 1-pl nor FVC, nor impedance components, i.e., respiratory resistance and reactance, were significantly different between groups either before or after albuterol administration ( Table 2) . Analysis of the main quality control indexes such as backextrapolation volume, time to peak flow, and tidal breathing pattern, viz., BF and minute ventilation (V E) did not reveal significant differences between groups (Table 3) . Moreover, there were no significant differences between groups concerning arterial blood gases, degree of dyspnea (MRC score), quality of life (SGRQ), physical performance (6MWD), and number of exacerbations per year (Table 4) . Postbronchodilator FEV 1-pl was significantly larger than FEV 1 (P Ͻ 0.0001) in both groups, but this difference was significantly larger in the dominant emphysema group than in chronic bronchitis group (P ϭ 0.0026). Consistent with these data, postbronchodilator FEV 1-pl was not significantly different between the dominant emphysema and the chronic bronchitis groups (Table 2 and Fig. 2) .
Grading the severity of disease using the old GOLD score by FEV 1 led to a significant (P ϭ 0.0115) excess of III to IV classes in the dominant emphysema group compared with the chronic bronchitis group (Fig. 3) . By using FEV 1-pl , the class distribution was not significantly different between groups (P ϭ 0.3162), and the proportion of subjects shifting from the III to IV to the I to II classes was significantly (P ϭ 0.0348) larger in the dominant emphysema group (16 out of 47) than in the chronic bronchitis group (8 out of 51). With the new GOLD grading system, the distribution of A to B and C to D stages was insignificantly different between groups using either FEV 1 or FEV 1-pl .
By using either spirometric FEV 1 or FEV 1-pl the BODE score was significantly higher in subjects with dominant emphysema than those with chronic bronchitis (P ϭ 0.0079) (Fig. 4) , but the difference between groups became significantly less (interaction P ϭ 0.0168) when FEV 1-pl was substituted for FEV 1 . By using either FEV 1 (P ϭ 0.0111) or FEV 1-pl (P ϭ 0.0324) there was a prevalence of more severe BODE stages in the dominant emphysema group than in the chronic bronchitis group. But the proportion of subjects shifting from the III-IV to the I-II stages by using FEV 1-pl instead of FEV 1 was significantly (P ϭ 0.0180) larger in the dominant emphysema group (9 out of 47) than in the chronic bronchitis (2 out of 51) group (Fig. 5) . 
DISCUSSION
The main results of the present study are the following: 1) FEV 1 was significantly less in subjects with dominant emphysema than those with chronic bronchitis; 2) FEV 1-pl , respiratory impedance parameters, arterial blood gases, and patientcentered variables, namely, dyspnea, quality of life, physical performance, and number of exacerbations per year were similar between groups; 3) the use of FEV 1-pl instead of FEV 1 resulted in a significant shift toward lower severity classes more in the dominant emphysema group than in the chronic bronchitis group; and 4) by using FEV 1 the BODE index was significantly higher in the dominant emphysema group than in the chronic bronchitis group, but this difference was significantly attenuated by using FEV 1-pl .
Interpretation of results. The use of FEV 1 as an index of severity of pulmonary disorders stems from the paper by Fletcher and Peto (13) suggesting that this parameter may decline with age at a faster rate in smokers than in healthy subjects. Further longitudinal studies in COPD showed, indeed, that FEV 1 is a predictor of either respiratory or all-cause mortality (4, 35) . Therefore, current guidelines and strategy documents have recommended the use of FEV 1 to stratify COPD subjects by severity (9, 25a, 26, 29, 31, 35) . However, the observation that FEV 1 is weakly correlated with patient-centered variables, such as dyspnea (37) , exercise tolerance (5), and health-related quality of life (16), has prompted the introduction of composite classification criteria (8, 35) . Furthermore, it has been recently proposed that a classification based not only on severity but also on phenotype may represent a step forward for personalized treatment of COPD patients (25) .
In whatever stratification system, the severity of lung function abnormality has been graded based on the FEV 1 (1, 2, 9, 25, 26, 27, 29, 31, 35) . In theory, this is justified by the fact that the FEV 1 reflects expiratory flow limitation, which is a marker of the disease. Yet, forced expiratory flow and thus FEV 1 are determined by different yet indistinguishable mechanisms, such as lung elastic recoil, resistance upstream from the flow limiting segment, and airway size and stiffness (17) . In addition, during a forced expiratory maneuver, part of intrathoracic gas is compressed as a result of an excess in alveolar pressure with respect to the critical pressure necessary to generate maximal flow (17, 18, 21) , thus causing the FEV 1 measured at the mouth to be lower than the simultaneous change in chest wall volume measurable by a body plethysmograph. This difference is small in healthy subjects but may become large in disease as a result of the increase in airflow resistance, or lung volume, or both (21, 32, 33) .
The present study is the first one in which the impact of thoracic gas compression on the severity classification of COPD has been examined in relation to dominant phenotypes. The findings show that FEV 1 measured at the mouth was consistently lower in subjects with dominant emphysema with respect to those with dominant chronic bronchitis despite similar patient-centered variables, blood gas data, and indexes of respiratory mechanics measured during tidal breathing by FOT. The fact that the two phenotypes did not differ for R 5 , R 19 , R [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and X 5 , which are very sensitive indexes of airway mechanics, and FEV 1-pl strongly suggests that the more severe reduction of FEV 1 observed in emphysema than chronic bronchitis phenotype is not a reflection of greater degree of airflow obstruction but rather a greater amount of TGCV. Although such a difference of FEV 1 could be due to different expiratory efforts, this possibility is presumably ruled out by the similarities of time to peak flow and back-extrapolation volume between groups. More likely, the differences in FEV 1 between phenotypes were due to larger lung volume in emphysema, as predicted on the ground of the wave-speed theory of expiratory flow limitation. During a forced expiration, alveolar pressure increases and gas is compressed within the lung, thus causing lung volume and lung elastic recoil to decrease. A reduction of elastic recoil pressure will result in a reduction of driving pressure and transmural pressure at choke point, which can explain why FEV 1 was systematically less than FEV 1-pl . The amount of thoracic gas compression being larger in larger lungs than smaller lungs, for a given pressure and airflow resistance, this would explain why the difference between FEV 1-pl and FEV 1 was greater in the dominant emphysema group than in the chronic bronchitis group.
The present results are in keeping with previous studies. Krowka et al. (21) found that decreasing expiratory effort was associated with a tendency of FEV 1 to increase above the threshold of natural variability and suggested that this negative Fig. 2 . Postbronchodilator FEV1-pl in subjects with dominant emphysema (Eϩ, n ϭ 47) or chronic bronchitis (CBϩ, n ϭ 51). Eϩ vs. CBϩ, P ϭ 0.1081; FEV1 vs. FEV1-pl, P Ͻ 0.0000; interaction, P ϭ 0.0026. This would indicate that gas compression significantly affected forced expiratory volume in both groups, but significantly more in Eϩ than CBϩ. Values are means and standard deviations. 1-pl in COPD subjects undergoing lung volume reduction surgery and found that about 40% of the increase in FEV 1 after surgery was explained by the reduction in the amount of thoracic gas compression.
Limitations of the study. The present study has limitations. First, no quantitative assessment of emphysema was made by high-resolution computed tomography (HRCT). However, the CRS model was validated against HRCT (28) , and, although a zone of overlap may be present, the two groups of this study exhibited values quite far from the cutoff value. Moreover, there were significant differences between groups in TLC and D L CO, which are strong correlates of anatomical emphysema (7) that were not included in the model. Thus it seems justified to assume that the method used for grouping subjects with dominant emphysema or chronic bronchitis was adequate for the purposes of this study. Second, predicting equations for FEV 1-pl are not available, and, therefore, predicted values were obtained by increasing predicted FEV 1 by a fixed amount determined in a group of healthy subjects. This might have determined systematic over-or underestimation of severity in both groups, but this would unlikely explain differences between groups. Third, because of its cross-sectional nature, the study cannot provide direct information on the prognostic role of different pulmonary function tests. Nevertheless, the present data show that thoracic gas compression could potentially affect the BODE index, which has been proposed as a sensitive predictor of mortality.
Clinical and therapeutic implications. The results of the present study have practical implications owing to the use of severity grading for choice of treatment (9, 25a, 26, 29, 31, 35) and prognosis (8) . Indeed, using FEV 1-pl instead of FEV 1 caused a shift from GOLD III-IV to GOLD I-II classes in a larger number of subjects with dominant emphysema than dominant chronic bronchitis. Were this classification used as a treatment guidance, more subjects with dominant emphysema would have received combined treatment with inhaled steroids than subjects with dominant chronic bronchitis even if clinical variables and airway mechanical conditions were not dissimilar. With the 2013 GOLD classification based on the FEV 1 , dyspnea, and exacerbation number, the use of FEV 1-pl instead of FEV 1 did not lead to significant differences between subjects with dominant chronic bronchitis or emphysema. We speculate that this is because of a relatively minor role for lung function with respect to dyspnea and exacerbations in this multidimensional grading system. The BODE index, albeit multidimensional, was affected by gas compression more in the dominant emphysema group than in the chronic bronchitis group. By using FEV 1-pl instead of FEV 1 the difference between the dominant emphysema group and the chronic bronchitis group was significantly reduced but still significant, presumably because of the lower BMI in the dominant emphysema group. Indeed, when a score including FEV 1-pl , MRC, and 6MWD, but not BMI, was calculated, there was no difference between the dominant emphysema group and the chronic bronchitis group (P ϭ 0.3249).
Conclusions. The present study challenges the use of FEV 1 as the sole lung function parameter for severity grading in COPD because of its dependence on dominant phenotype.
Assuming that lung function measurements are still needed to confirm objectively the clinical diagnosis COPD, the practical question is which tests are more adequate than spirometric FEV 1 to reflect COPD severity. An answer to this question will require longitudinal studies comparing the predicting value of Fig. 3 . Effect of thoracic gas compression on severity classifications of subjects with dominant emphysema (Eϩ, n ϭ 47) or chronic bronchitis (BCϩ, n ϭ 51) according to the 2007 GOLD criteria (left) and 2013 GOLD criteria (right). P values indicate significance of differences in categorical distributions between groups by using FEV1 or FEV1-pl. Fig. 4 . Effect of thoracic gas compression on the body mass, obstruction, dyspnea, and exercise (BODE) score in subjects with dominant emphysema (Eϩ, n ϭ 47) or chronic bronchitis (CBϩ, n ϭ 51). Eϩ vs. CBϩ, P ϭ 0.0079; FEV1 vs. FEV1-pl, P Ͻ 0.0000; interaction, P ϭ 0.0168. This would indicate that gas compression significantly affected forced expiratory volume in both groups, but significantly more in Eϩ than CBϩ. Values are presented as means and standard deviations. different lung function tests on clinical outcomes in relation to the major phenotypes of this complex disease. These should include not only the classical measurements of lung volumes and D L CO, but also tests that are independent of thoracic gas compression and sensitive to airway caliber and ventilation heterogeneity. DISCLOSURES R. Pellegrino, E. Crimi, R. Torchio, A. Antonelli, C. Gulotta, M. Baroffio, G. F. Sferrazza Papa, and V. Brusasco declare that no potential conflicts of interest exist with any companies and/or organizations whose products or services may be discussed in this article. A. Gobbi, R. Dellacà, and Politecnico di Milano University (institution of A. Gobbi and R. Dellacà) own stocks of a spin-off company involved in the development of forced oscillation devices.
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